Chapter 1: The Dilemma of Vaccination for Long-Haulers

Understanding the implications of vaccination for individuals suffering from long-term COVID symptoms is crucial. The key concern is whether those at risk for Autoimmune Syndrome Induced by Adjuvants (ASIA) should receive vaccines.

In 2011, Dr. Yehuda Shoenfeld, a prominent figure in the field of autoimmunity with over 1,700 research articles, introduced the concept of ASIA. This condition, also known as Shoenfeld's syndrome or post-vaccination autoimmunity, raises a significant question: Should individuals vulnerable to ASIA, like COVID long-haulers, get vaccinated?

Section 1.1: A Closer Look at ASIA

In medical terminology, an adjuvant refers to a substance that enhances the immune response triggered by a vaccine. Common adjuvants include alum, squalene, and certain mineral oils, which can also be found in products like silicone breast implants and cosmetic fillers.

The mechanisms behind ASIA are intricate and differ from person to person; however, the essential point is that certain individuals may have a more fragile immune system when responding to stimuli, which can lead to unpredictable immune reactions. Notably, those already predisposed to autoimmune conditions might be more susceptible, suggesting that the adjuvant in vaccines could be a catalyst for such responses.

ASIA has been documented following various types of vaccinations, including influenza shots, as highlighted in a 2013 review by Dr. Shoenfeld. The review noted that adverse reactions post-vaccination likely account for less than 0.01% of total vaccine administrations worldwide, although this figure might be skewed due to underreporting. Many of these reactions tend to be mild and self-limiting, with symptoms including fatigue, joint pain, sleep issues, and cognitive difficulties.

Subsection 1.1.1: Identifying Those at Risk

In a 2015 analysis, Dr. Shoenfeld's team reviewed various studies to pinpoint risk factors associated with ASIA. They concluded that certain individuals tend to develop ASIA more frequently, including:

• Those with a history of autoimmune reactions after vaccinations.
• Individuals with known allergies.
• People suffering from autoimmune disorders.
• Individuals at risk for autoimmunity, including those with a family history of autoimmune diseases, pre-existing auto-antibodies, and inadequate hormonal regulation.

While the aforementioned traits suggest a heightened risk for autoimmune diseases, quantifying the likelihood of ASIA remains challenging due to insufficient studies with robust control groups and sample sizes. As the review states, "The rarity of adverse events strongly suggests that the advantages of vaccines significantly outweigh the associated risks," advocating for the creation of safer, personalized vaccine options.

Chapter 2: Vaccination Considerations for COVID Long-Haulers

A recent study indicates that 13.1% of patients experiencing mild to moderate COVID-19—without prior thyroid issues—sustained thyroid damage, potentially leading to autoimmune disorders. This raises a question about the safety of mRNA vaccines for COVID long-haulers, who may already be experiencing symptoms like fatigue and cognitive fog due to unresolved inflammation or auto-antibodies.

"A potential concern is that some mRNA vaccines may trigger robust type I interferon responses, associated with both inflammation and potential autoimmunity," a 2018 study noted.

Given that COVID long-haulers might be categorized as individuals with autoimmune disorders, they may also be at risk for ASIA. This leads to an essential inquiry: Could vaccination exacerbate or reignite long-COVID symptoms?

While vaccines could hypothetically heighten the risk of ASIA in long-haulers, it is vital to weigh the risks of forgoing vaccination. Infections have been shown to initiate autoimmunity, suggesting that the dangers of post-infection autoimmunity could exceed those associated with post-vaccination autoimmunity. According to a review in The Lancet by three immunology experts, the latter presents significantly greater risks.

The European League Against Rheumatism (EULAR) recommends that individuals with autoimmune conditions should still receive vaccinations, albeit under a personalized plan to mitigate the heightened risks infections could pose. For example, live vaccines should be avoided, and vaccinations should ideally occur when the autoimmune condition is stable. The CDC also provides guidance on individuals who should consult healthcare providers prior to vaccination.

Even for highly effective vaccines like Pfizer's mRNA variant, the potential for ASIA should not be overlooked. As highlighted in a Nature Reviews Drug Discovery article, "A possible concern could be that some mRNA-based vaccine platforms induce potent type I interferon responses, which have been associated with both inflammation and potential autoimmunity." Identifying individuals at heightened risk for autoimmune reactions prior to mRNA vaccination may facilitate appropriate precautions.

Short Summary

Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA) emerged less than a decade ago and primarily affects those with existing autoimmune conditions or a family history of such diseases. Given that long-COVID can also be regarded as an autoimmune condition, it is prudent for COVID long-haulers to exercise caution and seek expert medical advice before vaccination.

For more current updates on this subject, please refer to the provided resources. Thank you for reading. To stay informed, consider subscribing to my Medium email list. If you wish to access Medium's unlimited features, feel free to use my referral link, which helps support my work.